NEW YORK (GenomeWeb) – Point-of-care diagnostics developer Sedia Biosciences has merged with genomic testing services provider Floragenex, the companies announced today.

Floragenex will now operate as a newly established subsidiary of Sedia, and will continue to offer its genomic services and solutions to life scientists. Sedia will also continue to offer its own Asanté assays for HIV and other infectious agents. Sedia CEO Roger Gale will remain CEO of the combined companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.